MedDataX Logo

Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

NCT ID: NCT06165718

Last Updated: 2023-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Artery Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Computed tomography pulmonary angiography indicated that there were intraluminal defects
* Malignant histopathology was sarcoma
* Informed consent form was signed

Exclusion Criteria

* Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
* Expected inability to complete follow-up
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The First Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role collaborator

Beijing Chao Yang Hospital

OTHER

Sponsor Role collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role collaborator

Sir Run Run Shaw Hospital

OTHER

Sponsor Role collaborator

Beijing Anzhen Hospital

OTHER

Sponsor Role collaborator

China-Japan Friendship Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wanmu Xie

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wanmu Xie

Role: PRINCIPAL_INVESTIGATOR

China-Japan Friendship Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wanmu Xie

Role: CONTACT

Phone: +86 15611734410

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wanmu Xie

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Roadmap for PAS-2022

Identifier Type: -

Identifier Source: org_study_id